Summary
Staging With MR Perfusion Imaging and MR Spectroscopy. ACRIN 6677 is conducted in collaboration with RTOG 0625: A Randomized Trial of Bevacizumab With Temozlomide in Recurrent Glioblastoma This was a multicenter phase 2 clinical trial by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group (now part of NRG) using ..... The objective of the ACRIN 6677 was to ..... Eligible patients were those 18 years and older with a histologically proven intracranial glioblastoma or gliosarcoma. There must be pathologic or imaging confirmation of tumor progression or regrowth. Primary Aim Findings: To assess the agreement between local interpretation and central interpretation of the standard MRI on the 6-month progression-free survival and to estimate the accuracy of local interpretation on the 6-month progression-free survival using central review as the reference standard. Advanced Imaging Component Objectives: To assess the potential role of perfusion MRI and MR spectroscopy imaging as an early indicator of response to the therapy after two weeks following initiation of treatment with bevacizum and to assess the potential role of perfusion MRI and MR spectroscopy imaging as a prognostic indicator based on images taken before treatment, 2 weeks following initiation of protocol treatment, and after every 2 cycles of treatment. Acknowledgements This shared data set was provided in collaboration with the American College of Radiology Core Lab. Many thanks are due to the ACRIN 6677 trial team, and all the patients participating in the study. This study was supported by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group (now part of NRG) which received funding from the National Cancer Institute through UXX CAXXXXXX and UXX CAXXXXXX.
Data Access
This is a limited access data set and is only available to members of NCI's Quantitative Imaging Network (QIN) with an anticipated public release of X/XX/XXXX. If you are a member of the QIN and would like to request access, please submit a CCP proposal to the QIN Coordinating Committee. Once access is granted, click the Download button to save a ".tcia" manifest file to your computer, which you must open with the NBIA Data Retriever. Click the Search button to open our Data Portal, where you can browse the data collection and/or download a subset of its contents.
| Data Type | Download all or Query/Filter |
|---|---|
| Images (DICOM, 86.9 GB) | |
Click the Versions tab for more info about data releases.
Detailed Description
Collection Statistics | |
|---|---|
Modalities | MR, CT |
Number of Patients | 123 |
Number of Studies | 566 |
Number of Series | 7629 |
Number of Images | 717,070 |
| Image Size (GB) | 86.9 |
Study Accrual:
Date Offsets:
All dates, like the visit date, are protected by presenting just the year; however, dates are also listed as offset days from the base date. The offset dates are used as a means of protecting patient information provided by the local sites in the original data, while allowing users to determine intervals between events. The standard DICOM date tags (i.e. birth dates, imaging study dates, etc.) have been de-identified so that all patients have a baseline study date of January 1, 1960. This falsified date represents the day patients were entered into trial database. The number of days between a subject’s longitudinal imaging studies are accurately preserved. A patient with a study performed on January 4, 1960 means the images were collected 3 days after the base date. For convenience, this calculation has been performed for all scans with the results inserted in DICOM tag (0012,0050) Clinical Trial Time Point ID. This means an imaging study that took place on January 4, 1960 would contain a value of "3" in tag (0012,0050).
Imaging Protocol:
Image Analysis:
Outcomes:
Schema
Metadata
Much more information about this data set (ACRIN 6677 / RTOG 0625) can be found https://www.acrin.org/6677_protocol.aspx
Citations & Data Usage Policy
This is a limited access data set and is only available to members of NCI's Quantitative Imaging Network (QIN) until XX/XX/XXXX. If you are a member of the QIN and would like to request access, please submit a CCP proposal to the QIN Coordinating Committee. Upon receiving access you may only use it for the purposes outlined in your proposal. You are not allowed to redistribute the data or use it for other purposes. See TCIA's Data Usage Policies and Restrictions for additional details. Questions may be directed to help@cancerimagingarchive.net.
Please be sure to include the following citations in your work if you use this data set:
Data Citation
Kinahan, Paul; Muzi, Mark; Bialecki, Brian; Herman Ben; Coombs, Laura. (2017). Data from the ACRIN 6677 Trial DSC-MR-Brain. Data from The Cancer Imaging Archive. (2019). http://doi.org (Coming soon).
TCIA Citation
Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, Journal of Digital Imaging, Volume 26, Number 6, December, 2013, pp 1045-1057. (paper)
Other Publications Using This Data
TCIA maintains a list of publications which leverage our data. At this time we are not aware of any publications based on this data. If you have a publication you'd like to add please contact the TCIA Helpdesk.
Version 1 (Current): Updated 2019/02/07
| Data Type | Download all or Query/Filter |
|---|---|
| Images (DICOM, 86.9 GB) | |